mifepristone

Product

Last mentioned: Mar 24, 2026

Timeline

  1. Media Backlash

    Health experts and advocacy groups label the bill's scientific claims regarding water pollution as unverified.

  2. Bill Introduction

    Rep. Mary Miller introduces the Clean Water For All Life Act in the House.

  3. Press Conference

    Miller and Kristan Hawkins (Students for Life) present the bill as an environmental protection measure.

  4. Law Signed

    Governor signs the law, enabling the Department of Corrections to begin distribution to providers.

  5. Legislation Passed

    Washington legislature passes bill to clarify state distribution authority.

  6. Missouri Stay Request

    DOJ files request in Missouri court to pause litigation pending FDA review.

  7. DOJ Missouri Filing

    DOJ quietly asks the Missouri court to pause proceedings pending FDA review.

  8. Missouri Pause Request

    DOJ files a request in federal court to pause the Missouri-led lawsuit citing an ongoing FDA review.

  9. Legislative Action

    Senator Josh Hawley introduces a Senate bill to outright ban the abortion pill.

  10. Legislative Action

    Sen. Josh Hawley introduces a Senate bill to outright ban the abortion pill.

  11. Hawley Federal Bill

    Senator Josh Hawley introduces a bill in the Senate to ban mifepristone nationwide.

  12. Louisiana Request

    DOJ asks Louisiana court to pause a similar lawsuit; request is largely ignored by the state.

  13. Louisiana Precedent

    DOJ unsuccessfully asks Louisiana to pause its separate anti-abortion lawsuit.

  14. Louisiana Pause Request

    DOJ asks Louisiana to pause its separate lawsuit; request is rejected by AG Liz Murrill.

  15. Amended Complaint

    AG Catherine Hanaway files amended complaint targeting mail-order abortion drugs.

  16. Amended Complaint

    AG Catherine Hanaway adds claims that mail-order drugs are dangerous without in-person visits.

  17. Lawsuit Filed

    Missouri, Kansas, and Idaho file suit against the FDA over mifepristone approval.

  18. Lawsuit Filed

    Missouri, Kansas, and Idaho file suit against the FDA over mifepristone regulations.

  19. Missouri Lawsuit Filed

    Missouri, Kansas, and Idaho file suit against the FDA to restrict mifepristone access.

  20. SCOTUS Ruling

    Supreme Court preserves access to mifepristone on standing grounds, but litigation continues.

Stories mentioning mifepristone 11

pharma Neutral

Medication Abortion Dominates US Market Amid Escalating Regulatory Warfare

Medication abortion has surged to account for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and mail-order access. This shift has catalyzed a sophisticated legal and legislative counter-offensive aimed at the FDA's regulatory authority and the distribution of pharmaceutical products.

2 sources
regulation Neutral

Medication Abortion Becomes Primary Method Amid Escalating Regulatory Warfare

Medication abortion now accounts for the majority of pregnancy terminations in the United States, driven by the expansion of telehealth and mail-order pharmacy access. This shift has sparked a sophisticated regulatory counter-offensive from opponents targeting FDA-approved protocols and cross-state digital health providers.

2 sources
pharma Very Bearish

Georgia Murder Charge Over Abortion Pills Signals New Pharma Legal Risks

A Georgia woman has been charged with murder after allegedly using medication to induce an abortion, marking a significant escalation in the criminalization of self-managed reproductive care. This case highlights the growing legal and regulatory volatility surrounding the distribution and use of FDA-approved abortion pills in restrictive jurisdictions.

7 sources
pharma Bearish

GOP Bill Targets Abortion Pill Access via Environmental Water Safety Regulations

House Republicans have introduced the Clean Water For All Life Act, a bill that seeks to restrict abortion pill access by framing fetal remains as environmental pollutants. The legislation would mandate 'catch kits' for patients, ban telehealth prescriptions, and impose severe criminal penalties including five-year prison sentences.

3 sources
regulation Bearish

GOP Bill Proposes 'Catch Kits' and Telehealth Ban for Abortion Pills

House Republicans have introduced the Clean Water For All Life Act, a novel regulatory attempt to classify abortion pill remains as environmental pollutants. The bill seeks to mandate 'catch kits' for patients, ban mail-order medication, and impose severe criminal penalties on providers and users.

3 sources
regulation Bearish

GOP's 'Clean Water For All Life Act' Targets Abortion Pills via EPA Regulation

House Republicans have introduced legislation that would criminalize flushing fetal remains, mandating the use of 'catch kits' for medical abortions to prevent alleged water contamination. The bill represents a novel attempt to use environmental protection frameworks to restrict reproductive healthcare access and ban telehealth services.

3 sources
pharma Neutral

Washington State Law Streamlines Abortion Pill Stockpile Distribution

Washington Governor has signed legislation authorizing the state to distribute its 30,000-dose stockpile of mifepristone to private and non-profit healthcare providers. The law resolves previous licensing hurdles that prevented the state's Department of Corrections from acting as a wholesale distributor for reproductive health medications.

2 sources
pharma Bearish

DOJ Seeks Pause in Missouri Mifepristone Suit Amid FDA Review Strategy

The Department of Justice has requested a federal court to pause a multi-state lawsuit against the FDA regarding the abortion pill mifepristone. The move suggests a strategic effort to allow the FDA to conduct its own internal review of the drug's safety and distribution protocols.

2 sources
regulation Bearish

DOJ Requests Pause in Missouri Mifepristone Lawsuit Citing Internal FDA Review

The U.S. Department of Justice has requested a federal court in Missouri to pause or dismiss a lawsuit targeting the FDA's approval of mifepristone, citing an ongoing internal agency review. This move reflects a strategic effort by the administration to manage high-stakes litigation over medication abortion and telehealth access ahead of the 2026 midterms.

2 sources
regulation Bearish

DOJ Seeks Strategic Pause in State-Led Mifepristone Litigation Amid FDA Review

The U.S. Department of Justice has requested federal courts in Missouri to pause litigation challenging the FDA's approval of mifepristone, citing an ongoing internal agency review. This tactical shift suggests a preference for administrative rulemaking over high-profile court battles as the administration navigates the legal complexities of reproductive health regulation.

2 sources